Kynurenines increase MRS metabolites in basal ganglia and decrease resting-state connectivity in frontostrriatal reward circuitry in depression

Xiangchuan Chen, Emory University
Diana J. Beltran, Emory University
Valeriya D. Tsygankova, Emory University
Bobbi J. Woolwine, Emory University
Trusharth Patel, Emory University
Wendy Baer, Emory University
Jennifer Felger, Emory University
Andrew Miller, Emory University
Ebrahim Haroon, Emory University

Journal Title: TRANSLATIONAL PSYCHIATRY
Volume: Volume 11, Number 1
Publisher: SPRINGERNATURE | 2021-09-04, Pages 456-456
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/s41398-021-01587-1
Permanent URL: https://pid.emory.edu/ark:/25593/vr6nm

Final published version: http://dx.doi.org/10.1038/s41398-021-01587-1

Copyright information:

© The Author(s) 2021

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).

Accessed November 16, 2022 7:16 PM EST
INTRODUCTION

Previous data has suggested that one mechanism by which inflammation can influence behavior is through effects on brain glutamate (Glu). Chronic administration of the inflammatory cytokine interferon (IFN)-alpha in patients with hepatitis C led to increased Glu in basal ganglia regions and anterior cingulate cortex measured using magnetic resonance spectroscopy (MRS) [1, 2]. Similar increases in basal ganglia Glu have also been reported in patients with major depression (MD) with increased endogenous inflammation, indexed by the acute phase reactant C-reactive protein (CRP) [3]. In each case, increased Glu in these brain regions was associated with increases in the overall severity of depressive symptoms and symptoms of anhedonia, amotivation, and psychomotor slowing [1–3]. Of note, anhedonia is rapidly emerging as a public health priority [4]. For instance, anhedonia is not only common in MD (rates of ~70%) but was associated with a ~30% increase in the risk of death and disability among depressed individuals [5]. Large-scale meta-analyses and reviews have linked the development of anhedonic symptoms with basal ganglia and related reward network dysfunction [6–8]. Increasing inflammation of the glial cells in the basal ganglia and related regions may account for reward circuit dysfunction and anhedonia in the inflammatory subtype of MD [3, 9, 10].

Astrocytes are primarily responsible for Glu uptake in synaptic and nonsynaptic areas and, consequently, are the major regulators of Glu homeostasis [11]. Astroglial dysfunction is a well-documented feature of mood disorders but may be particularly relevant to the inflammatory subtype of MD [12, 13]. MRS Glu and myo-inositol are believed to be index astroglial dysfunction and distress [14, 15]. Despite its presence in other tissues, myo-inositol is believed to be an astroglial marker, because it is highly concentrated in astroglial cells, as shown in in vivo NMR studies [14, 15]. Myo-inositol participates in astrocytic osmoregulation and is highly sensitive to inflammation and oxidative stress [14–16]. Accordingly, greater CRP concentrations in the cerebrospinal fluid (CSF) of MD patients were associated with increases in myo-inositol, a marker of astroglial distress in the basal ganglia, suggesting increased astroglial distress [3, 17].

Relevant to the impact of inflammation on Glu and astrocytic function, there has been an increasing interest in the potential role of metabolites of the kynurenine pathway (KP). Inflammatory stimuli such as lipopolysaccharide (LPS) and Bacillus
Calmette–Guérin (BCG) vaccine and inflammatory cytokines such as tumor necrosis factor (TNF) and IFN gamma activate the enzyme indoleamine 2,3 dioxygenase (IDO), which converts tryptophan (TRP) to kynurenine (KYN) [18–20]. Under homeostatic conditions, ~95% of TRP is converted into KYN, and its breakdown products culminating in the generation of nicotinamide adenine dinucleotide (NAD+), an important cellular energy source [21, 22]. KYN is then transported into the brain, where it is metabolized either into 3-hydroxykynurenine (3HK), anthranilic acid (AA), 3-hydroxanthranilic acid (3HAA), and quinolinic acid (QA) in microglia, tissue macrophages, and trafficking monocytes; or kynurenic acid (KYNA) in astrocytes, oligodendrocytes, and neurons [23–27]. KYN and 3HK gain access to the brain via the large neutral amino acid transporter (LAT-1) in the blood–brain barrier (BBB), leading to an excess of KP metabolism in the brain [28–30]. These data are consistent with findings in patients with MD, whereby path analyses have demonstrated that increased peripheral blood inflammatory markers are linked to increased peripheral blood KP metabolites are that in turn associated with increased CSF KP metabolites [31]. Of note, in the context of chronic immune activation, astrocytes generate large quantities of KYNA that can be converted into QA by adjacent macrophages and microglia [32]. KYN can also amplify local proinflammatory signaling via activation of the nod-like receptor protein (NLRP) –2 inflammasome complex in astrocytic cells [33].

KP metabolites influence glutamatergic activity in several distinct ways [34]. QA produced endogenously, may be an endogenous neurotoxin and gliotoxin at high concentrations [35]. Regarding the impact of KP metabolites on astrocytic regulation of Glu, QA directly promotes astrocytic Glu release, increases its cycling, and decreases its reuptake by astrocytic transporters [34, 35]. 3HK also increases astrocytic Glu release via the induction of reactive oxygen species, leading to activation of the system xC- antporter, which extrudes one molecule of Glu exchange for a molecule of cysteine that is used in the synthesis of the antioxidant glutathione [36, 37]. Another target for KP metabolites is the N-methyl-D-aspartate (NMDA)-Glur receptor on glutamatergic neurons, with QA acting as an agonist and KYNA acting as an antagonist and allosteric modulator at the glycine site [34, 35, 37].

These effects of KP metabolites in conjunction with inflammation on astrocytes and Glu cycling can contribute to excessive Glu release and spillover into the extrasynaptic space [38, 39]. Furthermore, the diffusion of the spillover Glu in the extracellular fluid leads to chaotic activation of extracellular NMDA receptors leading to disarrayed signaling [40–43]. Of note, patterns of spontaneous brain oxygen level-dependent (BOLD) oscillatory activity in rsfMRI offer an unprecedented opportunity to study chaotic functional brain activity [44–51]. More specifically, regional homogeneity (ReHo) quantifies the concordance in BOLD-oscillations between neighboring voxels. ReHo has been associated with regional pathology in brain disease models [10, 52–54]. We have previously reported that inflammation-associated increases in Glu were associated with decreased ReHo in the basal ganglia and several other brain regions associated with mood and reward processing [10].

Indeed, MD patients with concurrent increases in inflammation and CNS Glu exhibited ReHo decreases at the site of MRS acquisition and over a wider network of brain regions, particularly those involved in reward processing [10]. Impaired connectivity between regions with decreased ReHo was associated with greater depression, anhedonia, and psychomotor slowing [10]. Our previous data and those from other groups have consistently linked concurrent increases in inflammation and KP metabolism with depression, suicidality, anhedonia, and treatment nonresponse [31, 55–59]. These findings are also consistent with a rich literature linking the development of depression-like behavior in preclinical models (e.g., decreased sucrose preference, greater immobility on forced-swim or tail-suspension tests) following IDO-activation by inflammatory stimuli [20, 27, 60–63]. Finally, in laboratory animals, blocking KP activation through inhibition of IDO or inhibiting the transport of KYN into the brain using leucine or blocking of NMDA receptors with ketamine can reverse inflammation-induced depressive-like behavior [20, 30, 61, 63].

Nevertheless, no study has examined the associations of plasma and CSF KP metabolites with MRS and rsfMRI measures (Glu, myo-inositol, ReHo, and connectivity). We, therefore, examined the impact of plasma and CSF KP on brain chemistry and the function of basal ganglia using MRS and rsfMRI. We hypothesized that increased plasma or CSF KP measures would be associated with elevated MRS-signals of astroglial markers (Glu and myo-inositol), reduced ReHo, and decreased functional connectivity in BG and other reward-related brain regions, resulting in greater severity of anhedonia. Identifying such a biomarker/neuroimaging-based biosignature could help identify a distinct subgroup of depressed patients with increased inflammation who may respond to KP-targeted pharmacotherapeutics. Subjects presented herein represent a subset of patients recruited for an NIH-funded study on phenotyping depressed patients with increased inflammation and overlap with subjects that have appeared in previous reports (NCT01426997) [3, 10, 31, 64].

**PATIENTS AND METHODS**

**Study sample**

We included unmedicated subjects between the ages of 21–65 years with a primary diagnosis of MD based on Structured Clinical Interview for Diagnostic and Statistical Manual-IV (SCID-IV) [65] and a 17-item Hamilton Rating Scale for Depression score (HAMD-D) ≥18 [66]. Subjects with active suicidal ideation (score ≥2 on item #3 on HAM-D) were excluded from study participation and referred for treatment. All qualifying patients were monitored for safety (e.g., suicidality, worsening) and referred for further management if necessary. We determined study eligibility based on history and physical examination, psychiatric evaluation, laboratory testing, and electrocardiography. Presence of Axis I psychiatric disorders (other than anxiety); substance abuse/dependence within the past 6 months (SCID-IV criteria and urine drug testing); unstable medical disorders (needing multiple visits or medication changes); intake of psychotropic medications of any kind (other than pm benzodiazepines, last drug intake >72 h); or intake of medications known to affect the immune system (oral steroids, nonsteroidal anti-inflammatory agents) were exclusionary. Patients with autoimmune disorders or a history of cancer (other than basal cell skin cancer) were excluded. No individual was allowed to discontinue their current psychotropic medications for the study. The Institutional Review Board of Emory University approved the study, and all subjects provided written informed consent.

**Assessment of depression severity and anhedonia**

Standardized measures of depression severity were obtained using the 30-item Inventory for the Severity of Depression-Self-Rated Version (IDS-SR)—a scale that has been extensively used in previous studies by our and other groups [3, 64, 67, 68]. IDS-SR was completed in one sitting, and the patients were asked to choose the item response (0, 1, 2, or 3) that best described themselves over the past 7 days. The scale was scored by adding 28 of 30 items to obtain a total score ranging from 0–84, excluding items #11–12 (Appetite increase/decrease), and #13–14 (Weight increase/decrease)—per instructions from the developers [68]. In addition, items with ambiguous ratings including #9 (“Diurnal Variation of Mood” with two subitems 9A and 9B), #10 (“Quality of Mood” with difficulty in differentiating depression versus grief), and #25 (aches and pains with difficulty in differentiating items from other somatic symptoms) were excluded based on patient feedback. Hierarchical clustering of the remaining 23 individual IDS-SR items indicated that four anhedonia items (#8: “Response to Good or Desired Events,” #17: “View of My Future,” #19: “General Interest Excluding Sex,” and #22: “Interest in Sex”) tightly clustered together. Anhedonia was determined as a latent factor representing the above individual items rather than a composite summary score from specific questionnaires.

**Blood sampling and assays**

Blood sampling was conducted between 0800–1000 h, and all subjects sat quietly for 30 min before phlebotomy to minimize the impact of circadian...
College Station, TX, USA) to examine the association between MRS markers and KP metabolites after controlling for age, sex, race (Caucasian vs. African American), and body mass index (BMI). Independent models for each of the MRS markers (Glut and myo-inositol) and KP metabolites from each compartment (plasma and CSF) were used after partia ling out effects of covariate/control variables (age, sex, BMI, and race) per Frisch–Lovell–Waugh theorem. The analysis was geared to test the explanatory power of the primary variables of interest (primary model) and to examine the effect of adding or removing covariates upon these associations (auxiliary model). We conducted this analysis in two phases. The primary model used a plugin estimator consisting of k(10)- fold*resample(10) runs (total = 100 runs), and the secondary (sensitivity) analysis used an alternate estimators, including cross-validated (CV) and adaptive methods. Of note, noise factors induced by control covariates do not disrupt the primary (plugin) estimator than the auxiliary (cross- validated or adaptive) estimators. Partial least squares-structural equation modeling (PLS-SEM) was used to examine path effects and mediation anal ytical associations in Smart PLS [72]. Biomarkers (KP, immune), seed connectivity, and anhedonia items (of IDS-SR) were used as indicators to generate latent constructs (measures). The models that were further used to test hypotheses based on path associations (structural model). Moderation of these associations by covariates was testing using linear path models for continuously distributed variables (age, BMI) and using group comparison models for categorical covariates (sex, race). More details of the analysis plan are provided in Supplementary Information 3.

RESULTS

Background data

Forty-nine subjects with available KP and MRS measures were recruited, of whom 46 subjects with available plasma KP and MRS measures and 40 with KP and rsfMRI measures were included in the study. Details on sample availability is provided in Supplementary Information 4, and missing data information are provided in Supplementary Table 2. Background and clinical information are provided in Table 1. None of the missing biomarker data were imputed as it was adjudged that the missingness was not random. One subject did not answer item #22 on IDS-SR (item on Libido), and the result was imputed using low-rank approximation after verifying it was missing completely at random. The subjects were in moderate to severely depressed range based on HAM-D Scores (mean ± SD = 23.2 ± 3.2), aged between 21–64 (mean ± SD = 38.6 ± 10.9 years), and obese (BMI = 31.8 ± 7.9 kg/m²). 69% of the subjects were women, and African Americans comprised 65% of the study population. The high percentage of women is a characteristic of most depressed subject groups, and the high representation of African Americans is consistent with the study location (Atlanta, GA). Several values of CSF KYN, QA, and 3HAA were discarded due to estimation difficulties by BrainsOnline, Inc. Hence only 4 CSF KP metabolites (TRP, KYN, 3HK, and AA) and one ratio (CSF KYN/TRP) were available for analysis.

Plasma KNYA, QA, and KYN/QA association with MRS Glutamate

Using the cross-fit, partia ling out lasso, plasma QA (Fig. 1A) was positively (Cf = 0.53, 95% CI = (0.07,0.99), z = 2.41, p = 0.024) and plasma KNYA (Fig. 1B) was negatively (Cf = −0.40, 95% CI = (−0.74, −0.05), z = −2.25, p = 0.02) associated with left basal ganglia Glu. The associations survived multiple testing by using 100-fold resampling of each fold in the primary analysis and during the sensitivity analysis, indicating relative insensitivity to perturbation by covariate induced noise factors. None of the other metabolites were significantly associated with MRS markers. Plasma KNYA/QA ratio was negatively associated with left basal ganglia Glu (Fig. 1C, Cf(95% CI) = −0.40(−0.63, −0.16), z = −3.27, p = 0.001). The relationship between plasma KNYA, QA, KYN/QA was robust (survived 100-fold resampling) and was not perturbed by adding or removing covariate/control variables during sensitivity analysis using CV and adaptive estimations.

Statistical analysis—Lasso-inferential model

Penalizing, cross-fit, partia ling out (double machine learning), lasso-inferential models robust to collinearity were used in Stata v16 (Stata,
connectivity between these and other brain regions as a function of the four KP metabolites. After adjusting for multiple comparisons (voxel $p < 0.001$, cluster $p < 0.05$), the 4 KP measures were associated with decreased ReHo in a total of 12 ROIs. Besides, 19-decreased seed connectivities between these ROIs and other brain regions were also noted. Supplementary Tables 3, 4 and Supplementary Figs. 1–3 provides a full list of ReHo ROIs and seed connectivities related to the KP metabolites. In terms of voxel volume, ReHo decreases in the DMPFC and basal ganglia together accounted for 62% of total brain-wide ReHo decreases identified by all four KP metabolites (Fig. 2B). Additionally, 90% of seed-connectivity decreases explained by the above four KP measures also involved either DMPFC or basal ganglia ROIs (Fig. 2C).

CSF KP mediates the effects of plasma KP on DMPFC-basal ganglia connectivity (Fig. 2D). PLS-SEM was used for path analysis using Baron and Kenny’s four-step approach [73]. The mediation model included three factors, i.e., plasma KP- and CSF KP-factors (latent factors generated from KYN and 3HK from plasma and CSF, respectively), and DMPFC–basal ganglia connectivity factor correlated with metabolites used to derive CSF KP latent (including DMPFC-left basal ganglia, DMPFC-right basal ganglia, left basal ganglia-left basal ganglia, and left basal ganglia-right basal ganglia). All values reported in the path modeling were obtained using 10000-bootstrapped repetitions. Step 1 (path “c”) examined if plasma KP latent (predictor variable) was associated with DMPFC–basal ganglia connectivity latent. Plasma KP factor was associated with DMPFC–basal ganglia factor with a negative path (Cf(95% CI) = −0.56(−0.78, −0.37), $t = 3.36, p = 0.001$) with a strong effect size ($r$-sq = 0.31, Cohen’s $f$-sq = 0.45). Step 2 (path “a”) examined if CSF KP mediated the effect of plasma KP latent factor. In line with our previous reports [31], plasma KP factor was associated with CSF KP factor via a positive direct path (Cf(95% CI) = 0.67(0.45, 0.88), $t = 5.57, p < 0.001$). Step 3 (path “b”) examined if the association between latent factors representing CSF KP and DMPFC–basal ganglia remained significant after controlling for the effects of plasma KP. Connectivity latent) after controlling for plasma KP. CSF KP was negatively associated with DMPFC–basal ganglia connectivity association lost its previously noted significance in this step. Step 4 (path “c”) tested if CSF KP completely or partially mediated the plasma KP/DMPFC-basal ganglia association. CSF KP factor exerted a full-mediation effect on the association between plasma KP and DMPFC–basal ganglia (path “c’, Cf(95% CI) = −0.44 (−0.89, −0.18), $t = 2.35, p = 0.019$). The full-mediation effect by CSF KP on the association between plasma KP and DMPFC–basal ganglia connectivity had strong predictive power and replicability for both in-sample ($r$-sq difference = 0.20, $f$-sq = 0.41) and out-of-sample (blindfolding CV test $Q$-sq difference = 0.22, $f$-sq = 0.34) metrics.

Moderation of KP/connectivity associations by immune markers, BMI, and other covariates
Moderation of above path “c’” by immune markers (TNF/TNFFR2), BMI, age, sex, and race were examined. Plasma TNF/TNFFR2 was associated with DMPFC–basal ganglia connectivity latent via a negative path (Cf(95% CI) = −0.29(−0.55, −0.11), $t = 2.52, p = 0.01$). Plasma KP > CSF KP significantly mediated this association with a strong effect size (mediation effect Cf(95% CI) = −0.25 (−0.57, −0.09), $t = 2.02, p = 0.043$, $f$-sq = 0.31). A similar negative indirect association between BMI and DMPFC–basal ganglia connectivity was noted (Cf(95% CI) = −0.16(−0.39, −0.05), $t = 2.10, p = 0.03$), which was similarly mediated by Plasma > CSF KP (Cf(95% CI) = −0.16(−0.33, −0.05), $t = 2.27, p = 0.023$). Age, sex, and race did not exert moderating effects on the above paths. We were unable to compute the effect of obesity upon the path

---

**Table 1.** Demographic, clinical, and biological variables of the sample.

| Variable     | N (%) | Mean(Std Dev) | Min  | Max  |
|--------------|-------|---------------|------|------|
| Age (y)      | 49    | 38.6(10.9)    | 21   | 64   |
| Female       | 34    | 69%           |      |      |
| Male         | 15    | 31%           |      |      |
| Caucasian    | 17    | 17%           |      |      |
| African American | 32 | 65%           |      |      |
| BMI (kg/m²)  | 49    | 31.8(7.9)     | 19.6 | 52.3 |
| HAM-D        | 49    | 23.2(3.2)     | 18   | 32   |
| LBG Glu (mmol/kg) | 49 | 8.7(1)       | 6.4  | 10.8 |
| LBG myo-inositol (mmol/kg) | 49 | 4.9(0.9)     | 3.5  | 7.4  |
| Plasma TNF (pg/ml) | 49 | 5.5(2.2)   | 0.1  | 10.6 |
| Plasma TNFR2 (ng/ml) | 49 | 2.5(0.9) | 0.8  | 5.3  |
| Plasma TRP (µM) | 49 | 50.6(8.7)   | 35   | 73.4 |
| Plasma KYN (µM) | 49 | 1.6(0.4)     | 0.9  | 3.3  |
| Plasma KYNA (nM) | 48 | 37.4(17.7)  | 13.2 | 101  |
| Plasma AA (nM) | 47 | 6.1(2.4) | 2.6  | 13.8 |
| Plasma 3HK (nM) | 49 | 32.1(11.4) | 12.5 | 72.5 |
| Plasma 3HAA (nM) | 47 | 20.4(9.4) | 8.8  | 51.4 |
| Plasma QA (nM) | 49 | 432.8(140) | 184  | 733  |
| CSF TRP (µM) | 41 | 1.6(0.4)  | 0.5  | 2.5  |
| CSF KYN (nM) | 41 | 32.4(15.6)  | 13.7 | 96.2 |
| CSF KYNA (nM) | 36 | 1.5(0.7) | 0.7  | 3.7  |
| CSF AA (nM) | 42 | 2.5(0.8) | 1.3  | 5.3  |
| CSF 3HKYN (nM) | 42 | 4.8(5.2) | 1.3  | 21.4 |
| CSF QA (nM) | 37 | 20(10.6)  | 10.5 | 56.7 |

The table presents the background data of the sample. BMI body mass index, HAM-D 17-item Hamilton depression rating scale, LBG left basal ganglia, Glu glutamate, TNF tumor necrosis factor, TNFR2 tumor necrosis factor receptor type 2, TRP tryptophan, KYN kynurenine, KYNA kynurenic acid, AA antranilic acid, 3HK 3-hydroxykynurenine, 3HAA 3-hydroxyanthranilic acid, QA quinolinic acid, CSF cerebrospinal fluid.

**Plasma KYN/TRP and CSF 3HK associations with left basal ganglia myo-inositol**

Plasma KYN/TRP ratio was positively associated with left basal ganglia myo-inositol (Cf(95% CI) = 0.25(0.02, 0.48), $z = 2.17, p = 0.03$) only in the primary model. This association did not survive sensitivity analysis due to a strong interaction between myo-inositol and age. The potent oxidative stress-inducing molecule CSF 3HK (Fig. 1D) was associated with left basal ganglia myo-inositol (Cf(95% CI) = 0.45(0.19, 0.75), $z = 3.35, p = 0.001$) in the primary model after 100-fold repetitions. However, this association did not survive sensitivity analysis as age was independently associated with myo-inositol, while BMI impacted CSF 3HK. None of the other CSF KP makers or CSF KYN/TRP ratio were associated with MRS markers. The inset in Fig. 2A illustrates the MNI voxel used for acquisition.

**KP associations with rsfMRI measures (Fig. 2A):** Based on the above results, only KYN, 3HK, KYNA, QA, KYN/TRP, and KYNA/QA ratios in the plasma and KYN and 3HK in the CSF were used for ReHo analysis. Plasma KYNA, QA, and KYNA/QA yielded ReHo ROIs identical to those provided by KYN and 3HK (provided in Supplementary Information S). Accordingly, ReHo data correlated with plasma KYN, plasma 3HK, CSF KYN, and CSF 3HK were used from all 40 subjects. ReHo ROI correlated with the above four markers were used as originating seeds to identify altered

---

X. Chen et al.
model effects due to limitations in the number of subjects with a BMI > 30).

**DMPFC–basal ganglia connectivity/anhedonia association**

Anhedonia latent was developed using loading from four items (#8, 17, 19, 22) of IDS-SR that clustered together during hierarchical clustering, as shown in Fig. 3. Item #18: Capacity for Pleasure or Enjoyment was removed following redundancy analysis, as it failed to load adequately in its latent factor (loading coefficient < 0.5). Three of 19 connectivities plasma correlated with plasma KYN (DMPFC-DMPFC, DMPFC-left ventrolateral prefrontal region, DMPFC-left dorsolateral prefrontal region), and 1/19 related to CSF 3HK (DMPFC-left basal ganglia) were selected based on their significant loadings onto the path model predicting anhedonia factor (loading coefficient > 0.7). Path and loading coefficients are provided in Supplementary Tables 5–7. Step 1 (Fig. 4A) examined the direct relationship between KP-associated functional connectivity and anhedonia. A significant negative association was noted between the DMPFC–basal ganglia connectivity factor and the anhedonia factor (Cf(95% CI) = −0.56 (−0.77, −0.43), t = 6.0, p < 0.001), with a strong effect size (r-sq = 0.36, Cohen’s f-sq = 0.45). Step 2 involved combining all latent factors (plasma KP, CSF KP, DMPFC–basal ganglia connectivity, and anhedonia) within a single unified model, as illustrated in Fig. 4A. A higher-order path model was used to control for high covariance between plasma and CSF KP metabolites. A combined KP factor including both CSF and plasma KP (Cf(95% CI) = 0.39 (0.28, 0.58), t = 5.1, p < 0.001), plasma KP factor (Cf(95% CI) = 0.27 (0.20, 0.39), t = 5.13, p < 0.001), and CSF KP factor (Cf(95% CI) = 0.15 (0.01, 0.27), t = 3.5, p < 0.001) were all indirectly associated with anhedonia. Intriguingly the path from plasma KP to CSF KP to combined KP factor to DMPFC–basal ganglia connectivity to Anhedonia was significant (Cf(95% CI) = 0.1(0.05, 0.19), t = 2.7, p = 0.007).

**Associations between MRS metabolites and DMPFC–basal ganglia connectivity**

Details of this analysis are presented in Supplementary Information 6 and Supplementary Fig. 4. Power analysis, rigor, and reproducibility. Detailed power estimates and analyses are provided in Supplementary Information 8 and Supplementary Fig. 5. Most of our effect sizes (noted in appropriate sections) were in the strong effect size range with Cohen’s f-sq values >0.25. With a sample size of 40, alpha of 0.05, and power of 0.8, effect sizes >0.25 (for direct paths and linear models) and >0.2 (for mediation) were adequate to identify key effects. We have presented data on multiple resampled analyses and sensitivity analyses examining the impact of covariates and disruptive noise factors. The lasso-inferential models used 100-fold resampling of lasso coefficients, and PLS-SEM used 10,000-fold bootstrapped CI.

**DISCUSSION**

Herein, we report that plasma QA, KYN, and KYN/QA were associated with MRS signals of Glu in the left basal ganglia. Plasma KYN/TRP and CSF 3HK were associated with myo-inositol signals in the same region, although this association was subject to moderation by age and BMI. MRS Glu and myo-inositol are believed to index astroglial dysfunction and distress [14, 15]. The precise nature of the astroglial dysfunction in the inflammatory subtype of depression is not yet fully clarified. It is now widely accepted that MRS primarily measures intracellular Glu that exists at much higher concentrations (5–15 mM) compared with the lower concentrations of Glu (~5–10 μM) encountered in the extracellular space [74]. A neuronal-astrocytic neurotransmitter cycle exists in the brain in which Glu from the neuronal pool is released into the synaptic cleft as a neurotransmitter, taken up by astrocytes, converted to glutamine, and returned to the neuron in this synthetically inactive form and converted back to Glu [75, 76].
Neuronal Glu processing by the astroglia is an energy-intensive process involving an expenditure of two molecules of adenosine triphosphate for each molecule of Glu processed [75]. Under mild anesthesia, Glu-glutamine neurotransmitter cycling is believed to consume >80% of total glucose oxidation in the cell [75]. However, the energy costs of Glu neurotransmission need to be weighed against the energy demands induced by inflammation. For instance, when immune cells are stimulated in vitro, they consume ~25–30% more energy, which increases ~60% during acute infections [77]. Thus, MRS Glu build-up in inflammation may reflect...

---

**Fig. 2** KP-resting fMRI associations. A presents the primary resting-state functional magnetic resonance imaging (rsMRI) targets of kynurenine pathway (KP) metabolites identified using voxel-based analysis. The areas shaded in deep blue represent the regions of interest (ROI) that demonstrated altered regional homogeneity (ReHo) associated with plasma or cerebrospinal fluid (CSF) KP. Identification of ROIs was based on the correlation between kynurenine (KYN) or 3-hydroxykynurenine (3HK) in either the plasma or CSF. A detailed description of all ReHo seed-ROIs thus derived (total = 12 seeds) is presented in Supplementary Information 4. ROIs correlated with plasma KP are illustrated using red circles and CSF KP-related ROIs are illustrated using green circles. These ROIs were also set as the seeds in seed-to-whole-brain connectivity analysis. The red or green lines and the red or green uncircled dots represent the connectivity and targets, respectively. Connectivity z-scores correlated with plasma and CSF KP measures were derived after controlling for multiple comparisons (threshold = voxel $p < 0.001$, cluster $p < 0.05$). B presents a 10 × 10 dot plot depicting the region-wise distribution of voxels (measured using voxel volume = 1 cubic millimeter/voxel), demonstrating ReHo decreases. As is evident, 62% of voxels demonstrating decreased ReHo were located either in the dorsomedial prefrontal cortex (DMPFC), left (LBG), or right basal ganglia (RBG) regions, respectively. C demonstrates a similar dot plot demonstrating the distribution of KP-correlated connectivity disruptions between ReHo seed regions and other brain regions. As is evident, 95% of whole-brain connectivity decreases were associated with DMPFC-BG regions. D represents the overall plan of the path/mediation analyses. Plasma and CSF KP latent factors represent the individual contribution of kynurenine (KYN), 3-hydroxykynurenine (3HK) to each of these factors. DMPFC-basal ganglia (BG) latent factor comprises four different connectivities (DMPFC-LBG, DMPFC-RBG, LBG-LBG, and LBG-RBG). Path c examines the relationship between plasma KP and DMPFC-BG connectivity and Path a examines the association between plasma and CSF KP to each other. Path b examines if plasma KP impacts the association between CSF KP and DMPFC-BG connectivity. Path c' presents the model testing mediation by CSF KP of the relationship between plasma KP on DMPFC-BG connectivity.
the impaired processing capacity resulting from astrocytic distress. MRS Glu increases have been reported in various inflammatory and neuropsychiatric disorders [9]. Similarly, increases in myo-inositol signals have been associated with immune pathologies such as multiple sclerosis, human immunodeficiency virus (HIV), and hepatitis C virus infections [16]. Intriguingly, it has also been strongly associated with aging and neurodegenerative dementia [16].

KP metabolism may reflect the convergence of pathologies involving bioenergetic dysfunction, Glu-cycling, and astroglial distress. More recently, the transport of KP molecules across BBB via LAT-1 has been emphasized, as it may be targeted by leucine, a high-affinity blocker of KP transport across LAT-1 [30]. Upon entry via LAT-1, KYN, and 3HK may bind to the NLRP2-inflammasome in the astrocytes leading to amplification of neuroinflammatory response via activation of caspase-1 and nuclear factor kappa-B, culminating in the release of interleukin-1β [33]. Thus, KYN may by itself act as a danger-associated molecular pattern that stimulates astrocytic inflammation resulting in increases MRS Glu and myo-inositol. Basal ganglia is a highly vascularized region with many end arteries offering a rich BBB interface for such pathological immune-KP–brain interactions. Increasing inflammation of the glial cells in the basal ganglia region may account for at least some of the reward circuit dysfunction evident in this study.

KP was associated with impaired functional activity and connectivity within/between DMPFC–basal ganglia regions, which in turn was associated with anhedonic items of the IDS-SR. Optogenetic experiments indicate that both the top-down (DMPFC Glu systems) and bottom-up (brainstem dopamine systems) compete for functional dominance over the striatal regions to balance competing motivational demands [78]. While the bottom-up inputs convey prediction error reward signals, the top-down inputs adjust and reorient motivational priorities to facilitate longer-term or non-hedonic objectives. For instance, water (during dehydration) or rest (during inflammation and infection) may be preferred over more powerful, reinforcing hedonic stimuli such as sucrose water [79]. Impairments of DMPFC

---

**Fig. 3 Anhedonia–HCA clustering.** The figure depicts the dendrogram from hierarchical clustering of individual items on Inventory for Depressive Symptoms–Self Rated Version (IDS-SR). After removing items with ambiguous and unreliable scoring on IDS-SR (details in text), the remaining 23 items were clustered using hierarchical clustering with Ward’s agglomerative method. As noted, anhedonia items on IDS-SR (items #8, 17, 18, 19, and 22) clustered tightly together and were combined into an “Anhedonia” factor. Item #18: Capacity for Pleasure or Enjoyment was removed during redundancy analysis, as it failed to load adequately onto its latent factor.
might identify a distinct subgroup of depressed patients who may respond to targeted stimulation of this region [80]. DMPFC and its downstream connections have been proposed as promising stimulation targets using transcranial magnetic stimulation for anhedonic depression [81]. Our data build upon this developing literature by demonstrating that KP molecules specifically target the DMPFC–basal ganglia frontostriatal system.

A major thrust of this study is to focus our attention on the anhedonic subtype of depression. Anhedonia refers to a decreased ability to enjoy previously pleasurable experiences [82]. Anhedonia may be viewed as a transdiagnostic entity seen among many neuropsychiatric disorders [6–8]. Our data support conceptualizing anhedonia as a dysfunctional integration between top-down and bottom-up networks that regulate reward functions disrupted by inflammation and its downstream products such as KP molecules [4, 79].

The study’s strengths include an in-depth characterization of KP molecules across plasma and CSF compartments, chemical and functional profiling of frontostriatal brain regions, and relating brain changes to anhedonia. However, some caveats will need to be borne in mind. Firstly, our sample lacks a control group, although we intended to examine KP dysfunction specifically among depressed subjects. Induction of anhedonia among healthy subjects by immune stimulation is well known to engage similar top-down and bottom-up brain circuits. Secondly, our data is cross-sectional. Longitudinal or interventional studies will provide more insights into the above-noted interactions. Our sample is relatively small, though the effect sizes were strong enough to support the sample size in our power analysis. Limitations in obtaining reliable measurements for CSF KYNA and QA constrained our ability to examine their association with the imaging outcomes. Nevertheless, future studies are warranted to examine these relationships. The sample was drawn from and represents a limited universe of medication-free, depressed individuals who were willing to undergo MRI scanning and CSF sampling. Our focus on anhedonia may have excluded other depressive symptom dimensions of interest. Suicidality has been significantly related to KP metabolism over several studies.

Fig. 4 Connectivity-anhedonia associations. A presents the overall scheme of the path model between all the latent factors within a single, reflective, multilevel path model. Briefly, kynurenine (KYN) and 3-hydroxykynurenine (3HK) in plasma and CSF were loaded onto their respective plasma and CSF kynurenine pathway (KP) factors that loaded further onto a combined KP factor. The KP factor was then related to the dorsomedial prefrontal (DMPFC)–basal ganglia (BG) latent factor that was further linked to the anhedonia latent factor described earlier. DMPFC-BG latent factor was composed of both plasma and CSF connectivities selected based on factor loadings (loading coefficient > 0.7). Three of 4 of the above connectivities, DMPFC-DMPFC (right to left DMPFC), DMPFC-left ventrolateral prefrontal region (LVPFC), DMPFC-left dorsolateral prefrontal region (DLPFC), were correlated with plasma KYN, and 1/4, i.e., DMPFC-left basal ganglia (LBG) was correlated with CSF 3HK. The red-colored broken lines represent direct paths that combined to create an indirect or mediation effect. Step 1 (A) examined a direct relationship between functional connectivity and anhedonia. B–D represents linear associations between the latent factor scores, with the relationship expressed as Spearman ρ values. B represents the direct association between KP and DMPFC-BG connectivity (ρ = 0.74, p < 0.001), and C presents the direct association between DMPFC-BG connectivity and anhedonia (ρ = 0.55, p < 0.001). D represents the indirect association between KP and anhedonia mediated by DMPFC-BG connectivity (ρ = 0.39, p < 0.01). A mediation effect of the link between KP and anhedonia by connectivity and the relationship between plasma KP and anhedonia by CSF KP and connectivity was significant (details in text).
recruitment criteria for the study excluded patients with significant suicidal ideation. Given our focus on frontostriatal systems, we did not examine other brain networks. Of note, biological interpretations of the data are limited by the abstracted nature of resting functional connectivity metrics and the inability of MRS to capture extracellular Glu signals reliably.

In conclusion, the study’s findings indicate that KP increases among depressed subjects were associated with greater chemical and functional changes in key hub regions of the frontal-subcortical reward system, leading to an anhedonic depressive subtype. Targeting the peripheral KP system or its transfer into the brain are viable areas of interest. Besides, the effect of KP metabolites on brain chemistry may be mitigated by Glu modulating agents such as ketamine and riluzole. Similarly, the newly emerging field of glial protective agents may help ameliorate the toxic effects of inflammation and KP metabolites on the brain.

REFERENCES

1. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR, et al. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 2014;39:1777–85.
2. Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR, et al. Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: preliminary findings. Brain Behav Immun. 2015;46:17–22.
3. Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry. 2016;21:1351–7.
4. Attwells S, Setiawan E, Rusjan PM, Xu C, Hutton C, Rafiei D, et al. Translocator protein distribution volume predicts reduction of symptoms during open-label trial of celecoxib in major depressive disorder. Biol Psychiatry. 2020;88:649–56.
5. Dantzer R. Role of the kynurenine metabolism pathway in inflammation-induced depression: preclinical approaches. Curr Top Behav Neurosci. 2017;31:117–38.
6. Schwarz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol. 2004;4:12–17.
7. O’Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guérin. J Neurosci. 2009;29:4200–9.
8. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kerr SJ, Smythe GA, et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications for brain kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol. 2001;87:842–53.
9. Du F, Schmidt W, Okuno E, Kido R, Köhler C, Schwarz R. Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol. 1999;321:477–87.
10. Wejska K, Rzeski W, Okuno E, Kandefer-Szerszen M, Albrecht J, Turski WA. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenine acid synthesis in oligodendrocyte cell line (OLN-93). Neurochem Res. 2005;30:963–8.
11. Schwarz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465–77.
12. Dantzer R, O’Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2013;38:426–36.
13. Fukui S, Schwarz R, Rapoport SI, Takada Y, Smith QR, Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007–17.
14. Walker AK, Wing EE, Banks WA, Dantzer R. Leucine competes with kynurenine for transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 2019;24:1523–32.
15. Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, et al. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology. 2020;45:998–1007.
16. Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ, et al. Characterization of kynurenine pathway metabolism in human astrocytes and implications for brain kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol. 2001;87:842–53.
17. Zhang Q, Sun Y, He Z, Xu Y, Li X, Ding J, et al. Kynurenine regulates NL2P2 inflammatory signalling in astrocytes and its implications in depression. Brain Behav Immun. 2020;88:471–81.
18. Matute C, Domencq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia. 2006;53:212–24.
45. Dantzler R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
46. O’Connor JC, Lawson MA, André C, Biele EM, Szegedi SS, Lestage J, et al. Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol. 2009;182:3202–12.
47. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV. Washington DC: American Psychiatric Press; 1997.
48. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;25:36–62.
49. Ferlger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry. 2018;23:1358–65.
50. Ruzicka S, Pizzagalli DA, Sproule BA, Kennedy SH. Asssisting anhedonia in depression: potentials and pitfalls. Neurosci Biobehav Rev. 2016;65:21–35.
51. Lucido MJ, Behkhabat M, Goldsmith DR, Treadway MT, Haroon E, Felger JC, et al. Aiding and abetting anhedonia: impact of inflammation on the brain and pharmacologic implications. Pharm Rev. 2021 Jul;73:1084–117.
52. Covinsky KE, Cenzer IS, Yaffe K, O’Brien S, Blazer D. Dysphoria and anhedonia as risk factors for disability or death in older persons: implications for the assessment of geriatric depression. Am J Geriatr Psychiatry. 2014;22:606–13.
53. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irvin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68:748–54.
54. Harrison NA, Brydon L, Walker C, Gray MA, Steepe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66:407–14.
55. Harrison NA, Cooper E, Dowell NG, Keramida G, Voon V, Critchley HD, et al. Quantitative magnetization transfer imaging as a biomarker for effects of systemic inflammation on the brain. Biol Psychiatry. 2015;78:49–57.
56. Krishnadass R, Harrison NA. Depression phenotype, inflammation, and the brain: implications for future research. Psychosom Med. 2016;78:384–8.

ACKNOWLEDGEMENTS
This study was supported by grants R01MH087604 (A.H.M.), R01MH107033 (E.H.), K23MH091254 (E.H.), R01MH112076 (A.H.M. and E.H.), R01MH109637(J.C.F.), R21MH121891 (J.C.F. and A.H.M.), and R61MH121625 (J.C.F.) from the National Institute of Mental Health; UL1TR002378 (Georgia Clinical and Translational Alliance, Georgia CTSA) from the National Center for Advancing Translational Sciences, and by a Shared Instrumentation Grant (S10 grant S10OD016413-01 to the Emory University Center for Systems Imaging Core. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. We wish to thank Predicunt, Inc (https://predicunt.com/products/svem/) for providing free access to a trial version of the SVEM Software Module, used for analysis described in Supplementary Information 6.

AUTHOR CONTRIBUTIONS
X.C., E.H., J.C.F., and A.H.M. participated in data analysis and preparation of the paper. X.C. was blinded to clinical data and handled all scan analyses. B.J.W. conducted all clinical assessments and rating instruments but was blind to scan analyses. J.C.F. supervised all biological assays and supervised shipping of analytes to outside vendors and receipt of completed data. W.B., D.J.B., and V.D.T. participated in data collection, uploading to database, and following up with subjects. T.P. conducted all LPs.

COMPETING INTERESTS
Dr. Miller is a paid consultant to Boehringer Ingelheim. The remaining authors declare no competing interests.

ADDITIONAL INFORMATION

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
